Article info
Cancer genetics
Original research
Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing
- Correspondence to Dr George Zogopoulos, McGill University Health Centre, 1001 boul. Decarie, Rm EM2.3210, Montreal, Québec, Canada; george.zogopoulos{at}mcgill.ca
Citation
Oncology clinic-based germline genetic testing for exocrine pancreatic cancer enables timely return of results and unveils low uptake of cascade testing
Publication history
- Received June 24, 2021
- Accepted September 7, 2021
- First published September 23, 2021.
Online issue publication
July 21, 2022
Article Versions
- Previous version (23 September 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.